Anti-VEGF therapy resistance in neovascular age-related macular degeneration

Budzinskaia M.V.; Pliukhova A.A.; Sorokin P.A.

doi:https://doi.org/10.17116/oftalma20171334103-108

Close metadata

Recommended articles:

Choroidal neovascularization associated with choroidal nevi. Russian Annals of Ophthalmology. 2025;(1):104-112

Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116

Artificial intelligence in assessment of individual risks of age-related macular degeneration progression. Russian Annals of Ophthalmology. 2025;(2):123-128

Monocyte telomere length as a novel biomarker of macular atrophy and response to anti-VEGF therapy in age-related macular degeneration. Russian Annals of Ophthalmology. 2025;(6):52-61

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Curcumin-induced increased retinal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25

Efficacy of chemoimmunotargeted therapy in patients with advanced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Oncology. 2025;(3):63-70

Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resistance and adaptation to a changing environment. Molecular Genetics, Microbiology and Virology. 2025;(2):3-13

Potential and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medicine. 2025;(7):94-99

Amyloidogenesis and neurotrophic dysfunction in age-related macular degeneration in correlation with Alzheimer’s disease. Russian Journal of Archive of Pathology. 2025;(6):61-68

Abstract:

With account to the increase in the elderly population in most of the developed countries, the WHO defines age-related macular degeneration (AMD) as one of the main causes of blindness in the world. A large percentage of disability is accounted for by exudative, or neovascular, form of AMD. Today, a total of 5 anti-VEGF drugs exist that are recommended for treatment of exudative AMD: pegaptanib, ranibizumab, bevacizumab, aflibercept, and conbercept. Despite significant progress in the treatment of neovascular AMD yielded by the introduction into clinical practice of anti-VEGF drugs, some patients report a lack (down to complete lack) of response with standard treatment patterns and even a decrease in treatment efficacy after repeated intravitreal injections.

Keywords:

retina

age-related macular degeneration

anti-VEGF therapy

aflibercept

ranibizumab

bivacizumab

chroidal neovascularization

resistance

Authors:

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

SPIN RSCI: 3552-7061
Scopus AuthorID: 6508005851
ResearcherID: C-3026-2014
ORCID: 0000-0002-5507-8775

Pliukhova A.A.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Sorokin P.A.

Eyesight Recovery Center, 11 A, B, Rossolimo St., Moscow, Russia, 119021

Close metadata

References:

webpage on the Internet Prevention of Blindness and Visual Impairment. Priority Eye Diseases; 2012. Accessed May 6, 2016. Available at: https://www.who.int/blindness/causes/priority/en/index7.html
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738. https://doi.org/10.1016/S0140-6736(12)60282-7
Campa C, Costagliola C, Incorvaia C, et al. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010;2010:14. https://doi.org/10.1155/2010/546826
Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Over-expression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157(1):135-144. https://doi.org/10.1016/S0002-9440(10)64525-7
Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370(9583):204-206. https://doi.org/10.1016/S0140-6736(07)61104-0
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-1444. https://doi.org/10.1056/NEJMoa062655
Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. https://doi.org/10.1056/NEJMoa054481
Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. https://doi.org/10.1016/j.ophtha.2012.03.053
Heier JS, Brown DM, Chong V, et al. Schmidt-Erfurth U., VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548. https://doi.org/10.1016/j.ophtha.2012.09.006
Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). 1998;273(32):20556-20567.
Gragoudas ES, Adamis AP, Cunningham ET, Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816. https://doi.org/10.1056/NEJMoa042760
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007; 114(12):2179-2182. https://doi.org/10.1016/j.ophtha.2007.09.012
Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49(1):25-37.
Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411. https://doi.org/10.1016/j.ophtha.2012.04.015
Li X, Xu G, Wang Y, et al. AURORA Study Group Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121(9):1740-1747. https://doi.org/10.1016/j.ophtha.2014.03.026
Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014;98(7):951-955. https://doi.org/10.1136/bjophthalmol-2013-304736
Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 2015;29(6):721-731. https://doi.org/10.1038/eye.2015.48
Yazdi MH, Faramarzi MA, Nikfar S, Falavarjani KG, Abdollahi M. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. Expert Opin Biol Ther. 2015;15(9):1349-1358. https://doi.org/10.1517/14712598.2015
Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1-2. https://doi.org/10.1136/bjophthalmol-2011-301236
Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol.2014;92(8):713-723. https://doi.org/10.1111/aos.12463
Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J. 2015;159(3):426-436.e422. https://doi.org/10.1016/j.ajo.2014.11.022
Moon da RC, Lee DK, Kim SH, You YS, Kwon OW.Aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy refractory to anti-vascular endothelial growth factor. Korean J Ophthalmol. 2015;29(4):226-232. https://doi.org/10.3341/kjo.2015.29.4.226
Tranos P, Vacalis A, Asteriadis S, et al. Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther. 2013;7:485-490. https://doi.org/10.2147/DDDT.S43470
Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35.e22. https://doi.org/10.1016/j.ajo.2013.03.030
Brown DM, Chen E, Mariani A, Major JC, Jr, Group SS. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013;120(2):349-354. https://doi.org/10.1016/j.ophtha.2012.08.008
Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond). 2012;26(9):1181-1187. https://doi.org/10.1038/eye.2012.174
Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28(7):895-899. https://doi.org/10.1038/eye.2014.101
Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127(12):1596-1602. https://doi.org/10.1001/archophthalmol.2009.326
Kuroda Y, Yamashiro K, Miyake M, et al. Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology. 2015;122(11):2303-2310. https://doi.org/10.1016/j.ophtha.2015.06.053
Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15-22.e11. https://doi.org/10.1016/j.ajo.2013.02.017
Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug design, development and therapy. 2016;10:1857-1867. https://doi.org/10.2147/DDDT.S97653
Lim LS, Cheung CM, Wong TY. Asian age-related macular degeneration: current concepts and gaps in knowledge. Asia Pac J Ophthalmol (Phila). 2013;2(1):32-41. https://doi.org/10.1097/APO.0b013e31827ff5bc
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855-859. https://doi.org/10.1016/j.ophtha.2007.01.017
Ciardella AP, Donsoff IM, Yannuzzi LA. Polypoidal choroidal vasculopathy. Ophthalmol Clin North Am. 2002;15(4):537-554.
Yamamoto A, Okada AA, Kano M, et al. One-Year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122(9):1866-1872. https://doi.org/10.2147/OPTH.S101596
Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28(2):201-211. https://doi.org/10.1097/IAE.0b013e3181669504
Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina. 2008;28(3):375-384. https://doi.org/10.1097/IAE.0b013e3181619c55
Dansingani KK, Naysan J, Freund KB. En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation). Eye (Lond). 2015;29(5):703-706. https://doi.org/10.1038/eye.2015.27
Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996;103(12):2042-2053.
Scott AW, Bressler SB. Retinal angiomatous proliferation or retinal anastomosis to the lesion. Eye (Lond). 2010;24(3):491-496. https://doi.org/10.1038/eye.2009.311
Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2008;146(6):935-941.e931. https://doi.org/10.1016/j.ajo.2008.06.033
Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA, Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2009;93(5):610-613. https://doi.org/10.1136/bjo.2008.150995
Weber BH, CharbelIssa P, Pauly D, Herrmann P, Grassmann F, Holz FG. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int. 2014;111(8):133-138.